Pubblicazioni per linea Response

6 11, 2018

Marzia del Re et. al, The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response

Diatech Pharmacogenetics2018-11-06T14:24:10+01:00

1 10, 2018

E. Leoni et.al, Universal screening to identify lynch syndrome: two years of experience

Diatech Pharmacogenetics2018-12-04T12:14:58+01:00

3 07, 2018

Federico Pessina et. al, Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment

Diatech Pharmacogenetics2018-08-27T14:04:26+02:00

2 07, 2018

Laura Boldrini et. al, Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients

Diatech Pharmacogenetics2018-08-27T14:08:51+02:00

14 05, 2018

Eric Van Cutsem et. al, Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Diatech Pharmacogenetics2018-05-30T15:42:21+02:00

9 03, 2018

Lorena Gurrieri et. al, MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme”

Diatech Pharmacogenetics2018-04-12T15:39:06+02:00

12 01, 2018

Serena Trubini et al., Novel BRAF mutation in melanoma: A case report

Diatech Pharmacogenetics2018-02-01T13:12:10+01:00

27 12, 2017

Thibaut Kritter et. al, Radiomic Biomarkers Helps to Better Predict Progression Free Survival of Gliomas

Diatech Pharmacogenetics2018-03-08T13:56:50+01:00

4 12, 2017

Susanna Cappia et. al, Detection of EGFR mutations in archival lung cancer samples by pyrosequencing

Diatech Pharmacogenetics2017-12-04T16:12:04+01:00

4 12, 2017

Giovanna De Maglio et. al, Sequenziamento mediante pyrosequencing: un’analisi rapida e sensibile per la determinazione delle mutazioni di EGFR nel carcinoma polmonare non a piccole cellule

Diatech Pharmacogenetics2017-12-04T16:06:50+01:00

Precedente 345 Successivo